These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 9430199

  • 1. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro.
    Mollnes TE, Andreassen IH, Høgåsen K, Hack CE, Harboe M.
    Mol Immunol; 1997 Jul; 34(10):719-29. PubMed ID: 9430199
    [Abstract] [Full Text] [Related]

  • 2. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E, Platt JL, Frank MM.
    J Immunol; 1998 Feb 15; 160(4):1936-43. PubMed ID: 9469456
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE, Høgåsen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R.
    Scand J Immunol; 1998 Sep 15; 48(3):312-7. PubMed ID: 9743219
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
    Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefferer L, Rieben R.
    Vox Sang; 2009 Nov 15; 97(4):348-54. PubMed ID: 19656348
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
    Basta M, Fries LF, Frank MM.
    Blood; 1991 Aug 01; 78(3):700-2. PubMed ID: 1859883
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues.
    Frank MM, Basta M, Fries LF.
    Clin Immunol Immunopathol; 1992 Jan 01; 62(1 Pt 2):S82-6. PubMed ID: 1728991
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hemolysis upon intravenous immunoglobulin transfusion.
    Padmore RF.
    Transfus Apher Sci; 2012 Feb 01; 46(1):93-6. PubMed ID: 22169381
    [Abstract] [Full Text] [Related]

  • 16. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ, Ramsey J, Hammer CH, Frank MM.
    J Immunol; 1983 Jul 01; 131(1):403-8. PubMed ID: 6602833
    [Abstract] [Full Text] [Related]

  • 17. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg").
    Stangel M, Compston A, Scolding NJ.
    J Neuroimmunol; 2000 Mar 01; 103(2):195-201. PubMed ID: 10696915
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The interaction of immune serum globulin and immune globulin intravenous with complement.
    Bing DH.
    Mol Immunol; 1983 Aug 01; 20(8):893-900. PubMed ID: 6604863
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.